TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies Ltd. (OTC BB: TIKRF - News), today announced that it has signed an agreement to provide BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company, with $2.5 million in funding to continue development and clinical trials of its drugs for the treatment of bladder, ovarian and pancreatic cancers. Total funding in this round, together with other existing investors, will amount to approximately $3.7 million.
